LB Pharmaceuticals Inc
LBRX
$18.76
$0.271.46%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 09/30/2024 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 2.83M | 2.62M | 2.62M | 5.42M | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 5.25M | 5.29M | 5.29M | 16.08M | |
| Operating Income | -5.25M | -5.29M | -5.29M | -16.08M | |
| Income Before Tax | -3.56M | -5.09M | -5.09M | -14.18M | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -3.56M | -5.09M | -5.09M | -14.18M | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -3.56M | -5.09M | -5.09M | -14.18M | |
| EBIT | -5.25M | -5.29M | -5.29M | -16.08M | |
| EBITDA | -5.17M | -5.22M | -5.22M | -16.08M | |
| EPS Basic | -0.14 | -20.21 | -20.21 | -64.72 | |
| Normalized Basic EPS | -0.09 | -11.91 | -11.91 | -- | |
| EPS Diluted | -0.14 | -20.21 | -20.21 | -64.72 | |
| Normalized Diluted EPS | -0.09 | -11.91 | -11.91 | -- | |
| Average Basic Shares Outstanding | 25.30M | 251.80K | 251.80K | -- | |
| Average Diluted Shares Outstanding | 25.30M | 251.80K | 251.80K | 249.60K | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |